2 recruiting, 2 terminated, 1 not yet recruiting, 1 unknown. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 2, Terminated 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Terminated 2, Not yet recruiting 1, Recruiting 1 |
Follow RCC: new trials by email Literature Review of RCC trials Research Report on RCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients Vorolanib, cadonilimab - Kidney Cancer, RCC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 37 | 2024-08-31 | 2024-08-29 |
| Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) Cabozantinib 80 MG - RCC, Renal Cell Carcinoma | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 18 | 2023-12-20 | 2026-10-23 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 33 | 2019-05-20 | 2022-02-17 |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma Avelumab, Sunitinib - Clear-cell Renal Cell Carcinoma, RCC | Phase 2 | Withdrawn | Guru Sonpavde | 2017-05-23 | 2022-02-15 | |
| Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) Ixazomib, Pegylated IFN-alpha 2b - Metastatic Renal Cell Carcinoma, RCC | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 3 | 2015-08-14 | 2019-09-26 |
| Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） Anlotinib, Sunitinib maleate - Anlotinib, RCC | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 133 | 2013-12-01 | 2016-04-26 |
Carcinoma, Renal Cell (6) · Kidney Neoplasms (3) · Colorectal Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Rectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Adenocarcinoma (6) · Carcinoma (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Kidney Diseases (6) · Male Urogenital Diseases (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Urologic Diseases (6) · Urologic Neoplasms (6) · Neoplasms (5) · Kidney Neoplasms (3)
Sunitinib (2) · CB-839 (1) · anlotinib (1) · avelumab (1) · cabozantinib (1) · ixazomib (1) · talazoparib (1) · vorolanib (1)
A2 Biotherapeutics Inc. (1) · Calithera Biosciences, Inc (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Fox Chase Cancer Center (1) · Guru Sonpavde (1) · University of Texas Southwestern Medical Center (1)
United States (5) · China (1)
Guru Sonpavde, M.D. (1) · John Welch, MD, PhD (1) · Sam Whiting, MD, PhD (1) · Tian Zhang, MD (1)